|
市場調查報告書
躁鬱症
Bipolar Disorder: Can Competitive Advantage Be Established in a Challenging Market
|
本報告已在2011年12月21日停止出版。
因許多神經傳達物質介入引起的知名複雜疾病－躁鬱症，給準備開發新治療方法的製藥企業留下各種課題。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. （總公司：Massachusetts State），針對躁鬱症進行調查分析，並系統整理調查結果後出版報告書 "Bipolar Disorder: Can Competitive Advantage Be Established in a Challenging Market" 。
本報告書內容包括：躁鬱症的症狀、病態生理學、病因學背景介紹及目前的治療方法、經認可的治療藥的銷售動向、新興治療方法及未來市場發展預測等。共計21頁的內容綱要摘記如下：
實施概要
序章
躁鬱症概要
- 症狀、病態生理學、病因學背景
- 躁鬱症的種類
- 診斷、流行病學及躁鬱症的影響
目前針對躁鬱症的藥物治療
認可會有助於藥物的使用嗎
針對躁鬱症的新興治療方法
- 新的抗癲癇藥
- Janssen的Invega持續釋放型藥劑
- Organon的Asenapine
- Solvay/Wyeth/Lundbeck的Bifeprunox
- Vanda Pharmaceuticals的Iloperidone
- 治療惡化型躁鬱症的鈉・鈣通道調整劑
- Novartis的Licarbazepine
- Memory Pharmaceuticals的MEM-1003
- 治療躁鬱症的新對策
躁鬱症市場的未來發展前景
表
- 一般用於躁鬱症治療的藥物：2006年
- 躁鬱症治療用的新興藥物
- 躁鬱症治療用的主要藥物銷售金額：2006年
圖
- 主要市場中種類別躁鬱症的罹患案例：2006年
- 美國躁鬱症治療用抗精神病藥的銷售金額
- 美國躁鬱症治療用抗精神病藥的處方
- 美國躁鬱症治療用抗癲癇藥的銷售金額
- 美國躁鬱症治療用抗癲癇藥的處方
- 主要市場中躁鬱症治療藥的市場占有率：2006年
Abstract
Introduction
A poorly understood, complex disease that involves a number of
neurotransmitters, bipolar disorder presents several challenges for
pharmaceutical companies seeking to develop new treatments. While lithium and
several antiepileptic and antipsychotic agents are currently used to treat
either manic or mixed episodes of BPD, only Eli Lilly’s Symbyax and
AstraZeneca’s Seroquel have received FDA approval for treatment of
bipolar depression. The numerous unmet therapeutic needs resulting from the
incomplete understanding of BPD create significant opportunities within the
competitive BPD market.
Get the Answers You Need to Shape Your Strategy
Bipolar disorder represents a market with significant opportunity, but few
drug companies are actively developing new agents. What obstacles are
currently deterring companies from entering the BPD market? What challenges
need to be addressed, and what therapeutic needs remain unmet?
The treatment of depression associated with BPD has not been as extensively
studied as the treatment of either unipolar depression or bipolar mania.
What strategies does treatment of bipolar depression rely upon? Which
classes of antidepressants appear to be the most effective for treating
bipolar depression?
Several agents have received specifi c approval for treating BPD; other agents
are commonly used off-label. Which agents are most frequently used as
off-label treatments for BPD? What competitive advantages, if any, does FDA
approval provide? Which companies are specifi cally pursuing FDA approval for
their BPD agents?
Scope
- BPD background: Symptoms, pathophysiology, and etiology.
- Treatment options: Current therapies for the four common types of
episodes associated with bipolar I disorder and bipolar II disorder.
- Market dynamics: Sales growth statistics for BPD-approved agents
versus non-BPD-approved agents; sales and prescriptions of antipsychotics and
antiepileptics in the United States.
- Emerging therapies: Antipsychotics and sodium- and calcium-channel
blockers currently in development, along with novel approaches.
- Market outlook: Limitations of current BPD agents; challenges still
remaining; and the likelihood that any one agent will dominate the BPD market.
Companies Mentioned in This Spectrum Report
- Abbott Laboratories
- AstraZeneca
- Bristol-Myers Squibb
- Dainippon
- D-Pharm
- Eli Lilly
- Forest Laboratories
- Gedeon Richter
- GlaxoSmithKline
- Hoechst Marion Roussel
- Janssen
- Janssen-Cilag International
- Johnson & Johnson
- Kyowa Hakko
- H. Lundbeck
- Marinus Pharmaceuticals
- McNeil
- Memory Pharmaceuticals
- Novartis
- Organon
- Ortho-McNeil
- Otsuka Pharmaceutical
- Pfi zer
- Repligen
- Sanofi -Aventis
- Shire Pharmaceutical
- Solvay Pharmaceuticals
- Taisho
- Titan Pharmaceuticals
- Vanda Pharmaceuticals
- Wyeth
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Overview of Bipolar Disorder
- Symptoms, Pathophysiology, and Etiology
- Types of Bipolar Disorder
- Diagnosis, Epidemiology, and Impact of Bipolar Disorder
- Current Pharmacological Therapies for Bipolar Disorder
- Lithium
- Antiepileptic Agents
- Antipsychotic Agents
- Antidepressants
- Does Approval Aid Adoption?
- Emerging Therapies for Treatment of Bipolar Disorder
- Emerging Antipsychotic Agents
- Janssen’s Invega Extended-Release Tablets
- Organon’s Asenapine
- Solvay’s/Wyeth’s/Lundbeck’s Bifeprunox
- Vanda Pharmaceuticals’ Iloperidone
- Sodium- and Calcium-Channel Modulators in Development for Bipolar
Disorder
- Novartis’s Licarbazepine (LIC-477)
- Memory Pharmaceuticals’ MEM-1003
- Novel Approaches to the Treatment of Bipolar Disorder
- Outlook for the Bipolar Disorder Market
Tables:
- 1. Agents Commonly Used to Treat Bipolar Disorder, 2006
- 2. Emerging Agents for the Treatment of Bipolar Disorder
- 3. Sales of Leading Agents to Treat Bipolar Disorder, 2006
Figures:
- 1. Prevalent Cases of Bipolar Disorder by Type in the Major Markets, 2006
- 2. U.S. Sales of Antipsychotics Used in the Treatment of Bipolar Disorder
- 3. U.S. Prescriptions of Antipsychotics Used in the Treatment of Bipolar
Disorder
- 4. U.S. Sales of Antiepileptics Used in the Treatment of Bipolar Disorder
- 5. U.S. Prescriptions of Antiepileptics Used in the Treatment of Bipolar
Disorder
- 6. Regional Shares of Bipolar Disorder Treatment Sales in the Major
Markets, 2006
|
